

Lars Bertram

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2446129/publications.pdf>

Version: 2024-02-01

213
papers

27,277
citations

16451

64
h-index

6996

154
g-index

261
all docs

261
docs citations

261
times ranked

35969
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non- β -Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2023, 19, 807-820.	0.8	4
2	Effect of a common UMOD variant on kidney function, blood pressure, cognitive and physical function in a community-based cohort of older adults. <i>Journal of Human Hypertension</i> , 2022, 36, 983-988.	2.2	1
3	Relationship Between 5 Epigenetic Clocks, Telomere Length, and Functional Capacity Assessed in Older Adults: Cross-Sectional and Longitudinal Analyses. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 1724-1733.	3.6	17
4	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. <i>Molecular Psychiatry</i> , 2022, 27, 1990-1999.	7.9	9
5	Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals. <i>Nature Genetics</i> , 2022, 54, 437-449.	21.4	215
6	Region-based analysis of rare genomic variants in whole-genome sequencing datasets reveal two novel Alzheimer's disease-associated genes: DTNB and DLG2. <i>Molecular Psychiatry</i> , 2022, 27, 1963-1969.	7.9	9
7	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27.	10.8	30
8	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651.	3.4	20
9	Erratum to "Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Approach". <i>Movement Disorders</i> , 2022, 37, 1282-1283.	3.9	1
10	Effects of age, amyloid, sex, and ϵ -APOE on the CSF proteome in normal cognition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12286.	2.4	4
11	Genetic associations with learning over 100 days of practice. <i>Npj Science of Learning</i> , 2022, 7, 7.	2.8	2
12	Vitamin D supplementation is associated with slower epigenetic aging. <i>GeroScience</i> , 2022, 44, 1847-1859.	4.6	15
13	Genome-wide analysis furthers decoding of Alzheimer disease genetics. <i>Nature Reviews Neurology</i> , 2022, 18, 387-388.	10.1	7
14	Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci in older men and women. <i>Nature Communications</i> , 2021, 12, 654.	12.8	75
15	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.8	13
16	Self-reported sleep relates to microstructural hippocampal decline in β -amyloid positive Adults beyond genetic risk. <i>Sleep</i> , 2021, 44, .	1.1	5
17	Educational attainment does not influence brain aging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	49
18	Whole-genome sequencing reveals new Alzheimer's disease-associated rare variants in loci related to synaptic function and neuronal development. <i>Alzheimer's and Dementia</i> , 2021, 17, 1509-1527.	0.8	50

#	ARTICLE	IF	CITATIONS
19	BDNF serum concentrations in 2053 participants of the Berlin Aging Study II. <i>Neurobiology of Aging</i> , 2021, 101, 221-223.	3.1	4
20	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.8	23
21	Cohort profile: follow-up of a Berlin Aging Study II (BASE-II) subsample as part of the GendAge study. <i>BMJ Open</i> , 2021, 11, e045576.	1.9	24
22	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	3.5	9
23	Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach. <i>Movement Disorders</i> , 2021, 36, 2264-2272.	3.9	28
24	Clinico-genetic findings in 509 frontotemporal dementia patients. <i>Molecular Psychiatry</i> , 2021, 26, 5824-5832.	7.9	23
25	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicine</i> , 2021, 9, 1610.	3.2	7
26	A common polymorphism in the dopamine transporter gene predicts working memory performance and in vivo dopamine integrity in aging. <i>NeuroImage</i> , 2021, 245, 118707.	4.2	5
27	Individual variations in "brain age" relate to early-life factors more than to longitudinal brain change. <i>ELife</i> , 2021, 10, .	6.0	71
28	Berlin Aging Study II (BASE-II). , 2021, , 649-656.		0
29	Seven-CpG DNA Methylation Age Determined by Single Nucleotide Primer Extension and Illumina's Infinium MethylationEPIC Array Provide Highly Comparable Results. <i>Frontiers in Genetics</i> , 2021, 12, 759357.	2.3	7
30	Alzheimer's disease risk SNPs show no strong effect on miRNA expression in human lymphoblastoid cell lines. <i>Neurobiology of Aging</i> , 2020, 86, 202.e1-202.e3.	3.1	1
31	Genetic risk for Alzheimer disease predicts hippocampal volume through the human lifespan. <i>Neurology: Genetics</i> , 2020, 6, e506.	1.9	29
32	Genomic mechanisms in Alzheimer's disease. <i>Brain Pathology</i> , 2020, 30, 966-977.	4.1	29
33	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403.	4.8	42
34	Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia. <i>Clinical Genetics</i> , 2020, 98, 457-467.	2.0	13
35	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	2.6	7
36	Genetic risk scores and hallucinations in patients with Parkinson disease. <i>Neurology: Genetics</i> , 2020, 6, e492.	1.9	7

#	ARTICLE	IF	CITATIONS
37	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	2.6	13
38	APOE ϵ 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 65.	6.2	28
39	Self-reported Sleep Problems Related to Amyloid Deposition in Cortical Regions with High HOMER1 Gene Expression. <i>Cerebral Cortex</i> , 2020, 30, 2144-2156.	2.9	13
40	Identification of Novel Alzheimer's Disease Loci Using Sex-Specific Family-Based Association Analysis of Whole-Genome Sequence Data. <i>Scientific Reports</i> , 2020, 10, 5029.	3.3	31
41	Relationship between Lipoprotein (a) and cognitive function – Results from the Berlin Aging Study II. <i>Scientific Reports</i> , 2020, 10, 10636.	3.3	11
42	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792.	7.6	89
43	Disentangling the genetics of lean mass. <i>American Journal of Clinical Nutrition</i> , 2019, 109, 276-287.	4.7	38
44	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.8	46
45	Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2019, 15, 1468-1477.	0.8	106
46	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.8	62
47	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019, 15, 776-787.	0.8	134
48	Meta-analyses identify differentially expressed microRNAs in Parkinson's disease. <i>Annals of Neurology</i> , 2019, 85, 835-851.	5.3	84
49	Alzheimer disease risk genes: 29 and counting. <i>Nature Reviews Neurology</i> , 2019, 15, 191-192.	10.1	68
50	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019, 15, 644-654.	0.8	90
51	A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	3.7	70
52	Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE ϵ 4/TOMM40 long polyA repeat allele variants. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 814-824.	3.7	14
53	Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection. <i>Journal of the American College of Cardiology</i> , 2019, 73, 58-66.	2.8	147
54	Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. <i>Nature Genetics</i> , 2019, 51, 245-257.	21.4	536

#	ARTICLE	IF	CITATIONS
55	Berlin Aging Study II (BASE-II). , 2019, , 1-8.		3
56	Genotypeâ€Phenotype Relations for the Parkinson's Disease Genes <i>Parkin</i>, <i>PINK1</i>, <i>DJ1</i> MDSGene Systematic Review. Movement Disorders, 2018, 33, 730-741.	3.9	215
57	Healthy minds 0â€“100 years: Optimising the use of European brain imaging cohorts (â€œLifebrainâ€). European Psychiatry, 2018, 50, 47-56.	0.2	53
58	Aging and a genetic KIBRA polymorphism interactively affect feedback- and observation-based probabilistic classification learning. Neurobiology of Aging, 2018, 61, 36-43.	3.1	7
59	F1â€02â€04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P204.	0.8	0
60	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	6.2	64
61	The hSNM1B/Apollo variant rs11552449 is associated with cellular sensitivity towards mitomycin C and ionizing radiation. DNA Repair, 2018, 72, 93-98.	2.8	6
62	Taking genomics research to the next level: The Genotypeâ€Tissue expression project. Movement Disorders, 2018, 33, 1097-1097.	3.9	2
63	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	12.8	484
64	Field synopsis and systematic meta-analyses of genetic association studies in isolated dystonia. Parkinsonism and Related Disorders, 2018, 57, 50-57.	2.2	9
65	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	6.2	62
66	Evidence for a potential role of miR-1908-5p and miR-3614-5p in autoimmune disease risk using integrative bioinformatics. Journal of Autoimmunity, 2018, 94, 83-89.	6.5	15
67	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes and Endocrinology,the, 2017, 5, 97-105.	11.4	298
68	Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. Nature Communications, 2017, 8, 910.	12.8	118
69	Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. Nature Communications, 2017, 8, 80.	12.8	147
70	Association between lipoprotein(a) level and type 2 diabetes: no evidence for a causal role of lipoprotein(a) and insulin. Acta Diabetologica, 2017, 54, 1031-1038.	2.5	22
71	Launching the movement disorders society genetic mutation database (MDSGene). Movement Disorders, 2016, 31, 607-609.	3.9	54
72	<sc>N</sc>omenclature of genetic movement disorders: <sc>R</sc>ecommendations of the international <sc>P</sc>arkinson and movement disorder society task force. Movement Disorders, 2016, 31, 436-457.	3.9	228

#	ARTICLE	IF	CITATIONS
73	Gene-Environment Interaction in Parkinson's Disease: Coffee, <i>ADORA2A</i> , and <i>CYP1A2</i> . <i>Neuroepidemiology</i> , 2016, 47, 192-200.	2.3	35
74	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. <i>G3: Genes, Genomes, Genetics</i> , 2016, 6, 2073-2079.	1.8	13
75	Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. <i>Nature Genetics</i> , 2016, 48, 624-633.	21.4	870
76	Genome-wide association study identifies 74 loci associated with educational attainment. <i>Nature</i> , 2016, 533, 539-542.	27.8	1,204
77	Editorial. <i>Gerontology</i> , 2016, 62, 311-315.	2.8	98
78	Genome-wide gene-environment interaction analysis of pesticide exposure and risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 25-30.	2.2	31
79	Reply letter to Jinnah "Locus focus" and Albanese "Complex dystonia is not a category in the new 2013 consensus classification". Necessary evolution, no magic!. <i>Movement Disorders</i> , 2016, 31, 1760-1762.	3.9	1
80	Gene-environment interactions linking air pollution and inflammation in Parkinson's disease. <i>Environmental Research</i> , 2016, 151, 713-720.	7.5	55
81	Genetic Burden Analyses of Phenotypes Relevant to Aging in the Berlin Aging Study II (BASE-II). <i>Gerontology</i> , 2016, 62, 316-322.	2.8	11
82	Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature Genetics</i> , 2016, 48, 1462-1472.	21.4	284
83	Genetic variants linked to education predict longevity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13366-13371.	7.1	110
84	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	10.3	133
85	Prediction of Melanoma Risk in a Southern European Population Based on a Weighted Genetic Risk Score. <i>Journal of Investigative Dermatology</i> , 2016, 136, 690-695.	0.7	25
86	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
87	New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk. <i>Nature Communications</i> , 2016, 7, 10495.	12.8	245
88	Next Generation Sequencing in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2016, 1303, 281-297.	0.9	18
89	Lower baseline performance but greater plasticity of working memory for carriers of the val allele of the <i>COMT Val158Met</i> polymorphism. <i>Neuropsychology</i> , 2015, 29, 247-254.	1.3	33
90	Impact of Parkinson's disease risk loci on age at onset. <i>Movement Disorders</i> , 2015, 30, 847-850.	3.9	38

#	ARTICLE	IF	CITATIONS
91	Probing the Exome in Alzheimer Disease and Other Neurodegenerative Disorders. JAMA Neurology, 2015, 72, 389.	9.0	2
92	New insights into the genetics of X-linked dystonia-parkinsonism (XDP, DYT3). European Journal of Human Genetics, 2015, 23, 1334-1340.	2.8	73
93	Directional dominance on stature and cognition in diverse human populations. Nature, 2015, 523, 459-462.	27.8	173
94	Probing the epigenome by EWAS: A new era in brain disease research. Movement Disorders, 2015, 30, 197-197.	3.9	3
95	NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiology of Aging, 2015, 36, 1605.e7-1605.e12.	3.1	96
96	The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimer's and Dementia, 2015, 11, 1407-1416.	0.8	152
97	PLD3 gene variants and Alzheimer's disease. Nature, 2015, 520, E7-E8.	27.8	60
98	Adjusting heterogeneous ascertainment bias for genetic association analysis with extended families. BMC Medical Genetics, 2015, 16, 62.	2.1	9
99	Genome-wide significant association with seven novel multiple sclerosis risk loci. Journal of Medical Genetics, 2015, 52, 848-855.	3.2	34
100	A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nature Genetics, 2015, 47, 1121-1130.	21.4	2,054
101	Genome sequencing identifies a novel mutation in ATP1A3 in a family with dystonia in females only. Journal of Neurology, 2015, 262, 187-193.	3.6	7
102	Updated Field Synopsis and Systematic Meta-Analyses of Genetic Association Studies in Cutaneous Melanoma: The MelGene Database. Journal of Investigative Dermatology, 2015, 135, 1074-1079.	0.7	32
103	MicroRNA-138 is a potential regulator of memory performance in humans. Frontiers in Human Neuroscience, 2014, 8, 501.	2.0	49
104	The rare <i>TREM2</i> R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology, 2014, 83, 1353-1358.	1.1	40
105	The Val/Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene predicts decline in perceptual speed in older adults.. Psychology and Aging, 2014, 29, 384-392.	1.6	27
106	COMT polymorphism and memory dedifferentiation in old age.. Psychology and Aging, 2014, 29, 374-383.	1.6	31
107	A Web-based database of genetic association studies in cutaneous melanoma enhanced with network-driven data exploration tools. Database: the Journal of Biological Databases and Curation, 2014, 2014, bau101-bau101.	3.0	7
108	Lack of Replication of the GRIN2A-by-Coffee Interaction in Parkinson Disease. PLoS Genetics, 2014, 10, e1004788.	3.5	24

#	ARTICLE	IF	CITATIONS
109	Cohort Profile: The Berlin Aging Study II (BASE-II)â€. International Journal of Epidemiology, 2014, 43, 703-712.	1.9	213
110	Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging and Behavior, 2014, 8, 183-207.	2.1	161
111	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics, 2014, 46, 989-993.	21.4	1,685
112	Assessment of microRNA-related SNP effects in the 3â€² untranslated region of the IL22RA2 risk locus in multiple sclerosis. Neurogenetics, 2014, 15, 129-134.	1.4	19
113	Dopamine and glutamate receptor genes interactively influence episodic memory in old age. Neurobiology of Aging, 2014, 35, 1213.e3-1213.e8.	3.1	28
114	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochemical Pharmacology, 2014, 88, 426-449.	4.4	105
115	Dopamine modulates attentional control of auditory perception: DARPP-32 (PPP1R1B) genotype effects on behavior and cortical evoked potentials. Neuropsychologia, 2013, 51, 1649-1661.	1.6	23
116	Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature, 2013, 504, 432-436.	27.8	230
117	Dopaminergic Gene Polymorphisms Affect Long-term Forgetting in Old Age: Further Support for the Magnification Hypothesis. Journal of Cognitive Neuroscience, 2013, 25, 571-579.	2.3	35
118	Aging and KIBRA/WWC1 genotype affect spatial memory processes in a virtual navigation task. Hippocampus, 2013, 23, 919-930.	1.9	38
119	MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain, 2013, 136, 1778-1782.	7.6	60
120	Aging magnifies the effects of dopamine transporter and D2 receptor genes on backward serial memory. Neurobiology of Aging, 2013, 34, 358.e1-358.e10.	3.1	53
121	Effects of aging and dopamine genotypes on the emergence of explicit memory during sequence learning. Neuropsychologia, 2013, 51, 2757-2769.	1.6	26
122	O5-01-01: Biology meets bioinformatics: Validating the predicted role of Alzheimer's GWAS SNPs on micro-RNA function. , 2013, 9, P828-P828.		0
123	Distinguishing true from false positives in genomic studies: p values. European Journal of Epidemiology, 2013, 28, 131-138.	5.7	36
124	Ubiquilin-1 Modulates Î³-Secretase-Mediated Îµ-Site Cleavage in Neuronal Cells. Biochemistry, 2013, 52, 3899-3912.	2.5	14
125	Serum Iron Levels and the Risk of Parkinson Disease: A Mendelian Randomization Study. PLoS Medicine, 2013, 10, e1001462.	8.4	116
126	Genome-wide significant association ofANKRD55rs6859219 and multiple sclerosis risk. Journal of Medical Genetics, 2013, 50, 140-143.	3.2	34

#	ARTICLE	IF	CITATIONS
127	Elucidation of the BACE1 Regulating Factor GGA3 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 217-232.	2.6	22
128	Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database. <i>PLoS Genetics</i> , 2012, 8, e1002548.	3.5	495
129	On the Meta-Analysis of Genome-Wide Association Studies: A Robust and Efficient Approach to Combine Population and Family-Based Studies. <i>Human Heredity</i> , 2012, 73, 35-46.	0.8	6
130	Association of UBQLN1 mutation with Brownâ€“Viallettoâ€“Van Laere syndrome but not typical ALS. <i>Neurobiology of Disease</i> , 2012, 48, 391-398.	4.4	20
131	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , 2012, 49, 721-726.	3.2	94
132	Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29â€“000 subjects: Figure 1. <i>Journal of Medical Genetics</i> , 2012, 49, 558-562.	3.2	31
133	Genetic variants in PSEN2 and correlation to CSF β -amyloid42 levels in AD. <i>Neurobiology of Aging</i> , 2012, 33, 201.e9-201.e18.	3.1	6
134	Large-scale replication and heterogeneity in Parkinson disease genetic loci. <i>Neurology</i> , 2012, 79, 659-667.	1.1	119
135	Relationship between genetic risk factors and markers for Alzheimerâ€™s disease pathology. <i>Biomarkers in Medicine</i> , 2012, 6, 477-495.	1.4	25
136	Databases for neurogenetics: Introduction, overview, and challenges. <i>Human Mutation</i> , 2012, 33, 1311-1314.	2.5	3
137	The Genetics of Alzheimer's Disease. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 107, 79-100.	1.7	412
138	Toward modernizing the systematic review pipeline in genetics: efficient updating via data mining. <i>Genetics in Medicine</i> , 2012, 14, 663-669.	2.4	56
139	Genetics of Neurodegenerative Diseases. , 2012, , 719-736.		1
140	Developing the â€œnext generationâ€“of genetic association databases for complex diseases. <i>Human Mutation</i> , 2012, 33, 1366-1372.	2.5	5
141	Independent replication of STAT3 association with multiple sclerosis risk in a large German caseâ€“control sample. <i>Neurogenetics</i> , 2012, 13, 83-86.	1.4	21
142	Keeping up with genetic discoveries in amyotrophic lateral sclerosis: The ALSod and ALSGene databases. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 238-249.	2.1	82
143	The role of genetics for biomarker development in neurodegeneration. <i>Progress in Neurobiology</i> , 2011, 95, 501-504.	5.7	24
144	The future of Alzheimer's disease: The next 10 years. <i>Progress in Neurobiology</i> , 2011, 95, 718-728.	5.7	190

#	ARTICLE	IF	CITATIONS
145	Genetic Risk Factors: Their Function and Comorbidities in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-2.	2.0	1
146	Alzheimer's Disease-Associated Ubiquilin-1 Regulates Presenilin-1 Accumulation and Aggresome Formation. Traffic, 2011, 12, 330-348.	2.7	69
147	Call for participation in the neurogenetics consortium within the Human Variome Project. Neurogenetics, 2011, 12, 169-173.	1.4	5
148	Alzheimer's Genetics in the GWAS Era: A Continuing Story of "Replications and Refutations". Current Neurology and Neuroscience Reports, 2011, 11, 246-253.	4.2	36
149	Towards Unveiling the Genetics of Neurodegenerative Diseases. Seminars in Neurology, 2011, 31, 531-541.	1.4	56
150	Cysteine 27 Variant of the μ -Opioid Receptor Affects Amyloid Precursor Protein Processing through Altered Endocytic Trafficking. Molecular and Cellular Biology, 2011, 31, 2326-2340.	2.3	29
151	Comprehensive Field Synopsis and Systematic Meta-analyses of Genetic Association Studies in Cutaneous Melanoma. Journal of the National Cancer Institute, 2011, 103, 1227-1235.	6.3	92
152	Involvement of ubiquilin-1 transcript variants in protein degradation and accumulation. Communicative and Integrative Biology, 2011, 4, 428-432.	1.4	6
153	The Role of Clusterin, Complement Receptor 1, and Phosphatidylinositol Binding Clathrin Assembly Protein in Alzheimer Disease Risk and Cerebrospinal Fluid Biomarker Levels. Archives of General Psychiatry, 2011, 68, 207.	12.3	83
154	Quantifying Selective Reporting and the Proteus Phenomenon for Multiple Datasets with Similar Bias. PLoS ONE, 2011, 6, e18362.	2.5	50
155	Involvement of ubiquilin-1 transcript variants in protein degradation and accumulation. Communicative and Integrative Biology, 2011, 4, 428-32.	1.4	5
156	Evidence of Altered Posteromedial Cortical fMRI Activity in Subjects at Risk for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2010, 24, 28-36.	1.3	68
157	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	2.6	54
158	Systematic Analysis of Candidate Genes for Alzheimer's Disease in a French, Genome-Wide Association Study. Journal of Alzheimer's Disease, 2010, 20, 1181-1188.	2.6	63
159	Emerging role of Alzheimer's disease-associated ubiquilin-1 in protein aggregation. Biochemical Society Transactions, 2010, 38, 150-155.	3.4	42
160	Online-Datenbanken und systematische Metaanalysen komplex-genetischer Erkrankungen. Medizinische Genetik, 2010, 22, 235-241.	0.2	1
161	The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends in Genetics, 2010, 26, 84-93.	6.7	122
162	Somatic Mutation Profiles of MSI and MSS Colorectal Cancer Identified by Whole Exome Next Generation Sequencing and Bioinformatics Analysis. PLoS ONE, 2010, 5, e15661.	2.5	205

#	ARTICLE	IF	CITATIONS
163	The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. <i>Human Molecular Genetics</i> , 2010, 19, 526-534.	2.9	118
164	Correspondence to Sand et al. "Critical Reappraisal of a Catechol-O-Methyltransferase Transversion Variant in Schizophrenia" <i>Biological Psychiatry</i> , 2010, 67, e45-e48.	1.3	2
165	CALHM1 P86L polymorphism does not alter amyloid- β or tau in cerebrospinal fluid. <i>Neuroscience Letters</i> , 2010, 469, 265-267.	2.1	11
166	The Genetics of Alzheimer Disease: Back to the Future. <i>Neuron</i> , 2010, 68, 270-281.	8.1	728
167	Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. <i>Alzheimer's and Dementia</i> , 2010, 6, 265-273.	0.8	378
168	New light on an old CLU. <i>Nature Reviews Neurology</i> , 2010, 6, 11-13.	10.1	40
169	Obesity and the brain: a possible genetic link. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 27.	6.2	8
170	Genome-wide association studies in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2009, 18, R137-R145.	2.9	219
171	Assessment of Alzheimer's disease case-control associations using family-based methods. <i>Neurogenetics</i> , 2009, 10, 19-25.	1.4	65
172	Effects of Ubiquilin 1 on the Unfolded Protein Response. <i>Journal of Molecular Neuroscience</i> , 2009, 38, 19-30.	2.3	28
173	Maximizing the Power of Genome-Wide Association Studies: A Novel Class of Powerful Family-Based Association Tests. <i>Statistics in Biosciences</i> , 2009, 1, 125-143.	1.2	5
174	Recovering unused information in genome-wide association studies: the benefit of analyzing SNPs out of Hardy-Weinberg equilibrium. <i>European Journal of Human Genetics</i> , 2009, 17, 1676-1682.	2.8	32
175	Chapter 9 Alzheimer's Disease Genetics. <i>International Review of Neurobiology</i> , 2009, 84, 167-184.	2.0	55
176	GAB2 as an Alzheimer Disease Susceptibility Gene. <i>Archives of Neurology</i> , 2009, 66, 250-4.	4.5	37
177	Genome-wide Association Analysis Reveals Putative Alzheimer's Disease Susceptibility Loci in Addition to APOE. <i>American Journal of Human Genetics</i> , 2008, 83, 623-632.	6.2	423
178	The latest suspect. <i>Nature</i> , 2008, 454, 707-708.	27.8	31
179	Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. <i>Nature Reviews Neuroscience</i> , 2008, 9, 768-778.	10.2	664
180	Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. <i>Nature Genetics</i> , 2008, 40, 827-834.	21.4	961

#	ARTICLE	IF	CITATIONS
181	No Association between CALHM1 and Alzheimer's Disease Risk. <i>Cell</i> , 2008, 135, 993-994.	28.9	53
182	The genetics of Alzheimer's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 223-232.	1.8	2
183	Association of GSK3B With Alzheimer Disease and Frontotemporal Dementia. <i>Archives of Neurology</i> , 2008, 65, 1368-74.	4.5	86
184	Genetic Research in Schizophrenia: New Tools and Future Perspectives. <i>Schizophrenia Bulletin</i> , 2008, 34, 806-812.	4.3	40
185	Evaluation of the Potential Excess of Statistically Significant Findings in Published Genetic Association Studies: Application to Alzheimer's Disease. <i>American Journal of Epidemiology</i> , 2008, 168, 855-865.	3.4	40
186	Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population. <i>Journal of Medical Genetics</i> , 2007, 44, 606-608.	3.2	39
187	Decreased Catalytic Activity of the Insulin-degrading Enzyme in Chromosome 10-Linked Alzheimer Disease Families. <i>Journal of Biological Chemistry</i> , 2007, 282, 7825-7832.	3.4	89
188	Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease. <i>Human Molecular Genetics</i> , 2007, 16, 2703-2712.	2.9	52
189	The LDLR locus in alzheimer's disease: A family-based study and meta-analysis of case-control data. <i>Neurobiology of Aging</i> , 2007, 28, 18.e1-18.e4.	3.1	14
190	Follow-up mapping supports the evidence for linkage in the candidate region at 9q22 in the NIMH Alzheimer's disease Genetics Initiative cohort. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 220-227.	1.7	11
191	Exploring candidate gene associations with neuropsychological performance. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 987-991.	1.7	15
192	Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. <i>Nature Genetics</i> , 2007, 39, 17-23.	21.4	1,626
193	Single-Nucleotide Polymorphism rs498055 on Chromosome 10q24 Is Not Associated with Alzheimer Disease in Two Independent Family Samples. <i>American Journal of Human Genetics</i> , 2006, 79, 180-183.	6.2	11
194	Family-based association test for time-to-onset data with time-dependent differences between the hazard functions. <i>Genetic Epidemiology</i> , 2006, 30, 124-132.	1.3	18
195	Is Δ -T catenin (VR22) an Alzheimer's disease risk gene?. <i>Journal of Medical Genetics</i> , 2006, 44, e63-e63.	3.2	17
196	Ubiquilin 1 Modulates Amyloid Precursor Protein Trafficking and $A\beta$ Secretion. <i>Journal of Biological Chemistry</i> , 2006, 281, 32240-32253.	3.4	90
197	The genetic epidemiology of neurodegenerative disease. <i>Journal of Clinical Investigation</i> , 2005, 115, 1449-1457.	8.2	518
198	Genetics of Alzheimer's disease. , 2005, , 441-451.		1

#	ARTICLE	IF	CITATIONS
199	Family-Based Association between Alzheimer's Disease and Variants in <i>UBQLN1</i> . New England Journal of Medicine, 2005, 352, 884-894.	27.0	232
200	Twenty Years of the Alzheimer's Disease Amyloid Hypothesis: A Genetic Perspective. Cell, 2005, 120, 545-555.	28.9	1,644
201	Alzheimer's disease: one disorder, too many genes?. Human Molecular Genetics, 2004, 13, 135R-141.	2.9	177
202	The current status of Alzheimer's disease genetics: what do we tell the patients?. Pharmacological Research, 2004, 50, 385-396.	7.1	111
203	Partial Loss-of-Function Mutations in Insulin-Degrading Enzyme that Induce Diabetes also Impair Degradation of Amyloid β -Protein. American Journal of Pathology, 2004, 164, 1425-1434.	3.8	233
204	A QTL genome scan of the metabolic syndrome and its component traits. BMC Genetics, 2003, 4, S96.	2.7	50
205	Results of a high-resolution genome screen of 437 Alzheimer's Disease families. Human Molecular Genetics, 2003, 12, 23-32.	2.9	304
206	Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin. Human Molecular Genetics, 2003, 12, 2765-2776.	2.9	67
207	New Frontiers in Alzheimer's Disease Genetics. Neuron, 2001, 32, 181-184.	8.1	447
208	Family-Based Tests of Association in the Presence and Absence of Known Linkage. Genetic Epidemiology, 2001, 21, S292-7.	1.3	3
209	Of replications and refutations: The status of Alzheimer's disease genetic research. Current Neurology and Neuroscience Reports, 2001, 1, 442-450.	4.2	29
210	No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease. Annals of Neurology, 2001, 49, 114-116.	5.3	29
211	Dancing in the Dark? The Status of Late-Onset Alzheimer's Disease Genetics. Journal of Molecular Neuroscience, 2001, 17, 127-136.	2.3	31
212	Evidence against association of the FE65 gene (APBB1) intron 13 polymorphism in Alzheimer's patients. Neuroscience Letters, 2000, 296, 17-20.	2.1	18
213	The Genetics of Alzheimer's Disease. , 0, , 1-16.		0